Compare FDP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | RARE |
|---|---|---|
| Founded | 1886 | 2010 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1999 | 2013 |
| Metric | FDP | RARE |
|---|---|---|
| Price | $39.80 | $20.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $61.22 |
| AVG Volume (30 Days) | 213.0K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | $673,000,000.00 |
| Revenue This Year | N/A | $13.40 |
| Revenue Next Year | $3.75 | $42.83 |
| P/E Ratio | $21.47 | ★ N/A |
| Revenue Growth | 0.98 | ★ 20.13 |
| 52 Week Low | $29.00 | $18.41 |
| 52 Week High | $43.58 | $40.17 |
| Indicator | FDP | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 34.41 |
| Support Level | $34.76 | $19.61 |
| Resistance Level | $40.75 | $23.44 |
| Average True Range (ATR) | 1.02 | 0.79 |
| MACD | -0.39 | -0.12 |
| Stochastic Oscillator | 5.07 | 3.14 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.